Brian P Mckeon's most recent trade in Alkermes plc was a trade of 8,013 Ordinary Shares done . Disclosure was reported to the exchange on May 31, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2025 | 8,013 | 35,793 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2025 | 8,013 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.61 per share. | 31 May 2025 | 1,924 | 33,869 (0%) | 0% | 30.6 | 58,894 | Ordinary Shares |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 13,474 | 13,474 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 6,142 | 6,142 | - | - | Restricted Stock Unit Award | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 444.53 per share. | 14 Feb 2025 | 569 | 31,549 (0%) | 0% | 444.5 | 252,938 | Common Stock |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 308 | 615 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 308 | 31,819 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 303 | 303 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 303 | 31,511 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 299 | 894 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 299 | 32,118 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 252 | 0 | - | - | Restricted Stock Unit | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2025 | 252 | 31,208 (0%) | 0% | 0 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 05 Aug 2024 | 192 | 0 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 05 Aug 2024 | 192 | 31,048 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 05 Aug 2024 | 117 | 30,931 (0%) | 0% | 455.1 | 53,244 | Common Stock | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 29,245 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jun 2024 | 6,104 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.10 per share. | 29 Jun 2024 | 1,465 | 27,780 (0%) | 0% | 24.1 | 35,307 | Ordinary Shares |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 17,492 | 17,492 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 8,013 | 8,013 | - | - | Restricted Stock Unit Award | |
| IDEXX Laboratories | P. Mckeon Brian | EVP, CFO and Treasurer | 15 Feb 2024 | 483 | 0 | - | - | Incentive Stock Option (right-to-buy) | ||
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 15 Feb 2024 | 483 | 30,834 (0%) | 0% | 206.9 | 99,952 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 14 Feb 2024 | 5,355 | 5,355 | - | - | Non-Qualified Stock Option (right-to-buy) | ||
| IDEXX Laboratories | Mckeon Brian P. | EVP, CFO and Treasurer | 14 Feb 2024 | 1,193 | 1,193 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | P. Mckeon Brian | EVP, CFO and Treasurer | 14 Feb 2024 | 1,097 | 30,351 (0%) | 0% | 560.6 | 614,934 | Common Stock | |
| IDEXX Laboratories | Mckeon P. Brian | EVP, CFO and Treasurer | 14 Feb 2024 | 435 | 0 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | P. Brian Mckeon | EVP, CFO and Treasurer | 14 Feb 2024 | 435 | 30,152 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 14 Feb 2024 | 432 | 30,584 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 14 Feb 2024 | 432 | 0 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | P. Brian Mckeon | EVP, CFO and Treasurer | 14 Feb 2024 | 308 | 923 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 14 Feb 2024 | 308 | 31,448 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | P. Mckeon Brian | EVP, CFO and Treasurer | 14 Feb 2024 | 303 | 31,140 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 14 Feb 2024 | 303 | 606 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 14 Feb 2024 | 253 | 252 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | P. Brian Mckeon | EVP, CFO and Treasurer | 14 Feb 2024 | 253 | 30,837 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 14 Feb 2024 | 178 | 178 | - | - | Incentive Stock Option (right-to-buy) | ||
| Alkermes plc | P. Brian Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,533 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Mckeon Brian P. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,533 | 24,229 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.32 per share. | 10 Feb 2024 | 1,088 | 23,141 (0%) | 0% | 27.3 | 29,724 | Ordinary Shares |
| Alkermes plc | P. Brian Mckeon | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 523 | 26,692 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | P. Mckeon Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 313 | 15,990 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Mckeon P. Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 254 | 12,986 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Brian Mckeon P. | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 231 | 11,785 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | P. Mckeon Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 119 | 6,104 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | P. Brian Mckeon | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 90 | 4,639 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | P. Mckeon Brian | Director | Other type of transaction at price $ 0.00 per share. | 10 Feb 2024 | 88 | 4,533 | - | - | Restricted Stock Unit Award | |
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 07 Feb 2024 | 23,326 | 0 | - | - | Non-Qualified Stock Option (right-to-buy) | ||
| IDEXX Laboratories | P. Brian Mckeon | EVP, CFO and Treasurer | 07 Feb 2024 | 23,326 | 53,043 (0%) | 0% | 141.6 | 3,302,962 | Common Stock | |
| IDEXX Laboratories | P. Brian Mckeon | EVP, CFO and Treasurer | 07 Feb 2024 | 7,128 | 30,398 (0%) | 0% | 571.8 | 4,076,062 | Common Stock | |
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 07 Feb 2024 | 5,675 | 37,526 (0%) | 0% | 571.0 | 3,240,253 | Common Stock | |
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 07 Feb 2024 | 3,912 | 43,201 (0%) | 0% | 569.9 | 2,229,500 | Common Stock | |
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 07 Feb 2024 | 1,581 | 50,847 (0%) | 0% | 565.0 | 893,227 | Common Stock | |
| IDEXX Laboratories | Mckeon P. Brian | EVP, CFO and Treasurer | 07 Feb 2024 | 1,564 | 48,582 (0%) | 0% | 567.3 | 887,333 | Common Stock | |
| IDEXX Laboratories | Mckeon Brian P. | EVP, CFO and Treasurer | 07 Feb 2024 | 1,469 | 47,113 (0%) | 0% | 568.8 | 835,633 | Common Stock | |
| IDEXX Laboratories | P. Brian Mckeon | EVP, CFO and Treasurer | 07 Feb 2024 | 701 | 50,146 (0%) | 0% | 566.5 | 397,140 | Common Stock | |
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 07 Feb 2024 | 681 | 29,717 (0%) | 0% | 572.8 | 390,080 | Common Stock | |
| IDEXX Laboratories | Brian Mckeon P. | EVP, CFO and Treasurer | 07 Feb 2024 | 615 | 52,428 (0%) | 0% | 563.8 | 346,747 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 05 Aug 2023 | 192 | 3,704 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 05 Aug 2023 | 192 | 29,809 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 05 Aug 2023 | 117 | 29,692 (0%) | 0% | 504.1 | 58,977 | Common Stock | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2023 | 5,957 | 21,126 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.88 per share. | 07 Jul 2023 | 1,430 | 19,696 (0%) | 0% | 29.9 | 42,728 | Ordinary Shares |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 12,732 | 12,732 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2023 | 5,985 | 5,985 | - | - | Restricted Stock Unit Award | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 05 May 2023 | 560 | 29,605 (0%) | 0% | 178.3 | 99,826 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | EVP, CFO and Treasurer | 05 May 2023 | 560 | 0 | - | - | Incentive Stock Option (right-to-buy) | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 1,208 | 29,030 (0%) | 0% | 503.6 | 608,409 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 504 | 28,814 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 504 | 5,320 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 435 | 29,249 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 435 | 4,885 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 433 | 29,682 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 433 | 4,452 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 303 | 3,896 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 303 | 30,238 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 253 | 29,935 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2023 | 253 | 4,199 | - | - | Restricted Stock Unit | ||
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 4,445 | 15,169 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 4,445 | 4,445 | - | - | Restricted Stock Unit Award | |
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 08 Feb 2023 | 8,811 | 8,811 | - | - | Non-Qualified Stock Option (right-to-buy) | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 08 Feb 2023 | 1,231 | 5,824 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 08 Feb 2023 | 201 | 201 | - | - | Incentive Stock Option (right-to-buy) | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 05 Aug 2022 | 192 | 4,593 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 05 Aug 2022 | 192 | 28,365 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 05 Aug 2022 | 90 | 28,275 (0%) | 0% | 407.8 | 36,700 | Common Stock | |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 11,554 | 11,554 | - | - | Non Qualified Stock Option (Right to Buy) | |
| Alkermes plc | Brian P. Mckeon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jul 2022 | 5,957 | 5,957 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 11,519 (0%) | 0% | - | Ordinary Shares | |
| Alkermes plc | Brian P. Mckeon | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 7,585 | 0 | - | - | Restricted Stock Unit Award | |
| Alkermes plc | Brian P. Mckeon | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.19 per share. | 14 Jun 2022 | 795 | 10,724 (0%) | 0% | 27.2 | 21,616 | Ordinary Shares |
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 16 Feb 2022 | 706 | 28,153 (0%) | 0% | 141.6 | 99,970 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 16 Feb 2022 | 706 | 0 | - | - | Incentive Stock Option (right-to-buy) | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2022 | 10,502 | 10,502 | - | - | Non-Qualified Stock Option (right-to-buy) | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2022 | 1,212 | 6,870 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2022 | 964 | 27,447 (0%) | 0% | 505.5 | 487,331 | Common Stock | |
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2022 | 505 | 5,906 | - | - | Restricted Stock Unit | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2022 | 505 | 27,290 (0%) | 0% | 0 | Common Stock | ||
| IDEXX Laboratories | Brian P. Mckeon | Executive VP & CFO | 14 Feb 2022 | 459 | 6,411 | - | - | Restricted Stock Unit |